Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113394 | 0.81 | TP53 (0.76) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL17413886 | 0.80 | TP53 (0.74) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL10113519 | 0.79 | KMT2A (0.76) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL10113415 | 0.78 | TP53 (0.70) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL10113700 | 0.76 | LMNA (1.00) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL10113390 | 0.74 | KMT2A (0.73) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL10113404 | 0.74 | KMT2A (0.73) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL10279773 | 0.73 | LMNA (0.74) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL10113684 | 0.73 | KMT2A (0.71) | TP53KMT2AMEN1LMNAGAA | |
| SCHEMBL10113689 | 0.72 | KMT2A (0.66) | TP53KMT2AMEN1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | TP53 4573/4885KMT2A 4097/4885MEN1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.